{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:04:45Z","timestamp":1790111085610,"version":"4.0.1"},"reference-count":12,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jcf.2026.06.011","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:37:37Z","timestamp":1784288257000},"page":"817-818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Normalization of total bilirubin after switch from elexacaftor\/tezacaftor\/ivacaftor to vanzacaftor\/tezacaftor\/deutivacaftor in patients with cystic fibrosis and Gilbert\u2019s syndrome"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6525-9190","authenticated-orcid":false,"given":"Naehrig","family":"S","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breuling","family":"M","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10212","key":"10.1016\/j.jcf.2026.06.011_bib0001","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jcf.2026.06.011_bib0002","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jcf.2026.06.011_bib0003","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"PROMISE study group. Clinical effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in people with Cystic Fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2026.06.011_bib0004","volume":"32","author":"Sutharsan","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jcf.2026.06.011_bib0005","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.japh.2023.02.015","article-title":"Incidence of transaminitis in adults with cystic fibrosis taking elexacaftor\/tezacaftor\/ivacaftor","volume":"63","author":"Wood","year":"2023","journal-title":"J Am Pharm Associat"},{"key":"10.1016\/j.jcf.2026.06.011_bib0006","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/ppul.26831","article-title":"Gilbert\u2019s syndrome leads to elevated bilirubin after initiation of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis","volume":"59","author":"Patel","year":"2024","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.jcf.2026.06.011_bib0007","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jcf.2023.06.013","article-title":"Hyperbilirubinemia and Gilbert's syndrome in Cystic Fibrosis patients treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"22","author":"Terlizzi","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2026.06.011_bib0008","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s12890-024-03114-6","article-title":"Case Series: hyperbilirubinemia under elexacaftor\/tezacaftor\/ivacaftor in the presence of Gilbert's syndrome","volume":"24","author":"Weitzel","year":"2024","journal-title":"BMC Pulm Med"},{"issue":"4","key":"10.1016\/j.jcf.2026.06.011_bib0009","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/17425255.2023.2220960","article-title":"Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications","volume":"19","author":"Hong","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"10.1016\/j.jcf.2026.06.011_bib0010","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jcf.2023.01.005","article-title":"Drug-drug interactions with CFTR modulator therapy in cystic fibrosis: focus on Trikafta\u00ae\/Kaftrio\u00ae","volume":"22","author":"Purkayastha","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.011_bib0011","unstructured":"FDA Alyftrek prescribing information. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218730s000lbl.pdf."},{"key":"10.1016\/j.jcf.2026.06.011_bib0012","unstructured":"EMA Alyftrek: summary of product characteristics. www.ema.europa.eu\/en\/documents\/product-information\/alyftrek-epar-product-information_en.pdf."}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326016528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326016528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:06:55Z","timestamp":1790107615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326016528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1569199326016528"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.06.011","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Normalization of total bilirubin after switch from elexacaftor\/tezacaftor\/ivacaftor to vanzacaftor\/tezacaftor\/deutivacaftor in patients with cystic fibrosis and Gilbert\u2019s syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}